BNR Burning Rock Biotech Limited
NEUTRAL
Impact: 2/10
PRESS-RELEASE
Press release: activist
Price Chart
Loading chart...
Executive Summary
Burning Rock Biotech filed its 2025 annual report (Form 20-F) with the SEC, a routine regulatory requirement. The press release provides no financial results, guidance, or material business updates, making it a non-event for traders.
Actionable Insight
This filing is purely administrative with no trading implications. Monitor the actual 20-F filing for audited financials and any material changes in operations or risk factors.
Key Facts
- Filed 2025 annual report (Form 20-F) on April 28, 2026
- No financial data, guidance, or material updates disclosed in the press release
- Company focuses on NGS-based precision oncology testing and early detection
Financial Impact
No financial figures disclosed
Risk Factors
- No financial data provided to assess performance or trends
- Forward-looking statements carry standard regulatory risks
Market Snapshot
Exchange
Nasdaq
Sector
Services-Medical Laboratories
Analyst Consensus
80% bullish (5 analysts)
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3282392 |
2 reports for BNR
Track record builds as more directional reports settle.
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
|
Apr 28, 2026
22d ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Mar 12, 2026
9w ago
|
Press Release
| $22.85 $15.85 | ▼ −30.66% | ▼ −32.63% | $16.70 (−26.91%) |
Showing 2 of 2
US Market Status
Market Closed — Opens Thu (< 1m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access